Porfimer sodium

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Porfimer sodium
Porfimer Sodium.png
Clinical data
AHFS/Drugs.com Consumer Drug Information
Licence data EMA:Link, US FDA:link
Pregnancy cat.
Legal status
Routes Intravenous
Pharmacokinetic data
Bioavailability NA
Protein binding ~90%
Half-life 21.5 days (mean)
Excretion Fecal
Identifiers
CAS number 97067-70-4 N 87806-31-3
ATC code L01XD01
PubChem CID 57166
DrugBank DB00707
ChemSpider 10482283 YesY
UNII Y3834SIK5F N
ChEMBL CHEMBL1201707 N
Chemical data
Formula C68H74N8O11 (for n=0) 
Mol. mass 1179.36 g/mol (for n=0)
 N (what is this?)  (verify)

Porfimer sodium, sold as Photofrin, is a photosensitizer used in photodynamic therapy and radiation therapy and for palliative treatment of obstructing endobronchial non-small cell lung carcinoma and obstructing esophageal cancer.

Porfimer is a mixture of oligomers formed by ether and ester linkages of up to eight porphyrin units.[1] In practice, a red light source emitting at 630 nm is used to excite the Porfimer oligomers.[2]

Porfimer is Haematoporphyrin Derivative (HpD) (See PDT).

Approvals and indications[edit]

It was approved in Canada in 1993 for the treatment of bladder cancer.[2] It was approved in Japan in 1994 (for early stage lung cancer?).[2] It was approved by the U.S. FDA in December 1995 for esophageal cancer, and in 1998, it was approved for the treatment of early non-small cell lung cancer.[2]

In August 2003 the FDA approved its use for Barrett's esophagus.[3]

References[edit]

External links[edit]